209 related articles for article (PubMed ID: 38499025)
1. Immunotherapy in Non-small Cell Lung Cancer: a Review.
Sequeira T; Almodovar MT
Port J Card Thorac Vasc Surg; 2023 Oct; 30(3):55-65. PubMed ID: 38499025
[TBL] [Abstract][Full Text] [Related]
2. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
3. Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer.
Wu Z; Man S; Sun R; Li Z; Wu Y; Zuo D
Int Immunopharmacol; 2020 Aug; 85():106613. PubMed ID: 32450531
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy in Advanced Lung Cancer.
Huang J; Reckamp KL
Oncology (Williston Park); 2020 Jul; 34(7):272-279. PubMed ID: 32674216
[TBL] [Abstract][Full Text] [Related]
5. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
6. PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges.
Meng X; Liu Y; Zhang J; Teng F; Xing L; Yu J
Cancer Lett; 2017 Oct; 405():29-37. PubMed ID: 28688973
[TBL] [Abstract][Full Text] [Related]
7. The cutting-edge progress of immune-checkpoint blockade in lung cancer.
Zhou F; Qiao M; Zhou C
Cell Mol Immunol; 2021 Feb; 18(2):279-293. PubMed ID: 33177696
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in advanced non-small-cell lung cancer with
Liu F; Yuan X; Jiang J; Chu Q
Immunotherapy; 2020 Nov; 12(16):1195-1207. PubMed ID: 32985295
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?
Ahern E; Solomon BJ; Hui R; Pavlakis N; O'Byrne K; Hughes BGM
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083418
[TBL] [Abstract][Full Text] [Related]
10. East Asian patients who received immunotherapy-based therapy associated with improved survival benefit in advanced non-small cell lung cancer: An updated meta-analysis.
Yao Y; Li B; Xu Y; Yang L; Zou B; Wang L
Cancer Med; 2024 Feb; 13(4):e7080. PubMed ID: 38457254
[TBL] [Abstract][Full Text] [Related]
11. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
Front Immunol; 2021; 12():646874. PubMed ID: 33927719
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives.
Lazzari C; Spagnolo CC; Ciappina G; Di Pietro M; Squeri A; Passalacqua MI; Marchesi S; Gregorc V; Santarpia M
Curr Oncol; 2023 Mar; 30(4):3684-3696. PubMed ID: 37185393
[TBL] [Abstract][Full Text] [Related]
13. Tumor Immunology and Immunotherapy of Non-Small-Cell Lung Cancer.
Cascone T; Fradette J; Pradhan M; Gibbons DL
Cold Spring Harb Perspect Med; 2022 May; 12(5):. PubMed ID: 34580079
[TBL] [Abstract][Full Text] [Related]
14. The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice.
Zouein J; Haddad FG; Eid R; Kourie HR
Immunotherapy; 2022 Feb; 14(2):155-167. PubMed ID: 34865502
[TBL] [Abstract][Full Text] [Related]
15. Navigate Towards the Immunotherapy Era: Value of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Brain Metastases.
Yang G; Xing L; Sun X
Front Immunol; 2022; 13():852811. PubMed ID: 35422812
[TBL] [Abstract][Full Text] [Related]
16. Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.
Yan Y; Wang X; Liu C; Jia J
BMC Pulm Med; 2022 Apr; 22(1):166. PubMed ID: 35484541
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art.
Kang J; Zhang C; Zhong WZ
Cancer Commun (Lond); 2021 Apr; 41(4):287-302. PubMed ID: 33689225
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes.
Doroshow DB; Sanmamed MF; Hastings K; Politi K; Rimm DL; Chen L; Melero I; Schalper KA; Herbst RS
Clin Cancer Res; 2019 Aug; 25(15):4592-4602. PubMed ID: 30824587
[TBL] [Abstract][Full Text] [Related]
19. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
20. Role of CTLA Inhibition in Management of Non-Small Cell Lung Cancer.
Kerrigan K; Puri S
Curr Oncol Rep; 2022 Jan; 24(1):113-123. PubMed ID: 35060001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]